EVA1-Antibody Drug Conjugate Is a New Therapeutic Strategy for Eliminating Glioblastoma-Initiating Cells

0
153
Hybridoma cells were generated by immunizing BALB/c mice with EVA1-Fc fusion protein. The reactivity of the supernatant from these hybridoma cells was examined using EVA1-overexpressing cells and glioblastoma-initiating cells. Candidate antibodies were further selected using Biacore surface plasmon resonance analysis and two cytotoxicity assays, antibody-dependent cell cytotoxicity and complement-dependent cytotoxicity
[Neuro-Oncology]
Full Article